CDDO-Im NEW
| Price | $31 | $72 | $113 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-16 |
Product Details
| Product Name: CDDO-Im | CAS No.: 443104-02-7 |
| Purity: 98.3% | Supply Ability: 10g |
| Release date: 2024/11/16 |
Product Introduction
Bioactivity
| 名稱 | CDDO-Im |
| 描述 | CDDO-Im (TP-235) is an activator of Nrf2 and PPAR (Kis: 232/344 nM for PPARα/PPARγ). |
| 細胞實驗 | CDDO-Im is dissolved in DMSO. SUM159 and MDA-MB-231 cells are seeded into each well of 96-well plates (1,000 cell/well) and treated the next day with vehicle control or CDDO-Im (1, 10, 50, 100 and 200 nM) for given incubation time. The absorbance is measured with a spectrophotometer to determine the cell proliferation rate [2]. |
| 動物實驗 | Mice are injected i.p. with thioglycollate, and the resulting resident peritoneal macrophages are activated 3 days later with an i.p. injection of IFN-γ. CDDO and CDDO-Im are injected i.p. 30 min after IFN-γ. Macrophages are harvested 10 h later, cultured for 12 h, and then assayed for expression of iNOS protein and production of nitric oxide (NO) [1]. |
| 體外活性 | CDDO-Im effectively suppresses the proliferation of human leukemia and breast cancer cell lines (IC50 approximately 10-30 nM). In U937 leukemia cells, it induces monocytic differentiation, evidenced by increased CD11b and CD36 expression [1]. CDDO-Im treatment causes G2/M-phase cell cycle arrest and apoptosis in triple-negative breast cancer cell lines SUM159 and MDA-MB-231, significantly inhibiting CD24?/EpCAM+ cells in SUM159 tumorspheres. It also decreases sphere-forming efficiency and size in both primary and secondary cultures [2]. Moreover, CDDO-Im elevates Nrf2 protein levels, which increases the expression of antioxidant and detoxification genes regulated by Nrf2 [3]. |
| 體內(nèi)活性 | CDDO-Im exhibits strong inhibition of de novo inducible nitric oxide synthase (iNOS) expression in primary mouse macrophages. Additionally, it effectively suppresses the proliferation of B16 murine melanoma and L1210 murine leukemia cells in vivo. Administering 10 nM (5.4 μg) of CDDO-Im significantly impedes the induction of iNOS by IFN-γ, while a dose as low as 1 nmol (0.54 μg) of CDDO-Im shows partial effectiveness [1]. |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 40 mg/mL (73.84 mM), Sonication is recommended. H2O : Insoluble |
| 關鍵字 | inhibit | Ferroptosis | Keap1-Nrf2 | RTA 403 | CDDO Im | Inhibitor | TP 235 | Peroxisome proliferator-activated receptors | CDDO-Im | RTA403 | CDDOIm | TP235 | PPAR |
| 相關產(chǎn)品 | TBHQ | Acetylcysteine | α-Vitamin E | Daidzein | Sorafenib | Curcumin | Artemisinin | L-Cystine | L-Glutamic acid monosodium salt | Coenzyme Q10 | Naringenin | 2,3-Butanediol |
| 相關庫 | 抗胰腺癌化合物庫 | 經(jīng)典已知活性庫 | 抗糖尿病庫 | 抗肥胖化合物庫 | 線粒體靶向庫 | 抗衰老化合物庫 | 已知活性化合物庫 | 抗癌化合物庫 | 抗癌活性化合物庫 | 抗高血壓化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $96.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-12 | |
| $3700.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $99.00/1 PCS |
Amikon Limited
|
2019-01-29 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY